Auditory Complications among Childhood Cancer Survivors and Health-

- 2 related Quality of Life: A PanCareLIFE study
- 3 Sven Strebel^{1,2,3*}, Katja Baust^{4*}, Desiree Grabow⁵, Julianne Byrne⁶, Thorsten Langer⁷,
- Antoinette am Zehnhoff-Dinnesen⁸, Rahel Kuonen^{1,9}, Annette Weiss^{1,10}, Tomas Kepak¹¹, 4
- Jarmila Kruseova¹², Claire Berger^{13,14}, Gabriele Calaminus⁴, 5
- Grit Sommer^{1,15,16*}, Claudia E. Kuehni^{1,17*™}, and on behalf of the PanCareLIFE Consortium 6
- 7 ¹ Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- 8 ² CANSEARCH research platform in pediatric oncology and hematology, Department of Pediatrics, Gynecology
- 9 and Obstetrics, University of Geneva, Geneva, Switzerland
- 10 ³ Graduate School for Health Sciences, University of Bern, Bern, Switzerland
- 11 ⁴ Department of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany
- 12 ⁵ Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical
- 13 Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg
- 14 University Mainz, Mainz, Germany
- 15 ⁶Boyne Research Institute, Drogheda, Ireland
- 16 ⁷ Department of Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck,
- 17 Germany

1

- 18 ⁸ Department for Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhems University,
- 19 Münster, Germany
- 20 ⁹ Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- 21 ¹⁰ Bavarian Care and Nursing Authority, Amberg, Germany
- 22 11 University Hospital Brno & International Clinical Research Center (FNUSA-ICRC), Masaryk University,
- 23 Brno, Czech Republic
- 24 ¹² Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and
- 25 University Hospital Motol, Prague, Czech Republic
- 26 ¹³ Department of Pediatric Hematology and Oncology, University-Hospital, Saint-Étienne, France
- 27 ¹⁴ Lyon University, Jean Monnet University, INSERM, U 1059, Sainbiose, Saint-Étienne, France
- 28 ¹⁵ Department of Pediatric Endocrinology, Diabetology and Metabolism, Inselspital, Bern University Children's
- 29 Hospital, University of Bern, Bern, Switzerland
- 30 ¹⁶ Department of BioMedical Research, University of Bern, Bern, Switzerland
- 31 ¹⁷ Division of Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital,
- 32 University of Bern, Bern, Switzerland
- 33 *these authors contributed equally; [™]Corresponding author

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

perpetuity.

It is made available under a CC-BY 4.0 International license .

- 34 Correspondence to: Claudia E. Kuehni, Prof. MD; Institute of Social and Preventive
- 35 Medicine, University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland; E-mail:
- 36 claudia.kuehni@ispm.unibe.ch; Telephone: +41 31 684 35 07
- 37 **Key words:** childhood cancer; survivorship; quality of life; hearing loss;
- 38 Tinnitus

39 Abbreviations

| BMI | Body Mass Index |
|-----|-----------------|
| BP | Bodily pain |

CCS Childhood cancer survivors

CCSS American Childhood Cancer Survivor Study

CH Switzerland

CI 95% Confidence interval CNS Central nervous system

Coef. Estimated beta coefficient from linear regression

CRT Cranial radiation therapy
CZ The Czech Republic

DE Germany FR France

GH General health

HRQoL Health-related quality of life

HSCT hematopoietic stem cell transplantation

ICCC-3 International Classification of Childhood Cancer, Third edition

IQR Interquartile range

MCS Mental component summary

MH Mental health PCL PanCareLIFE

PCS Physical component summary

PF Physical functioning
RE Role emotional
RP Role physical

SCCSS Swiss Childhood Cancer Survivor Study

SF Social functioning

SF-36 Short-Form 36 questionnaire

VT Vitality

ABSTRACT

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

Auditory complications are potential side effects from childhood cancer treatment. Yet, limited evidence exists about the impact of auditory complications—particularly tinnitus—on health-related quality of life (HRQoL) among childhood cancer survivors (CCS). We determined the prevalence of hearing loss and tinnitus in the large European PanCareLIFE cohort of CCS and examined its effect on HROoL. We included CCS from four European countries who were diagnosed at age ≤ 18 years; survived ≥ 5 years; and aged 25–44 years at study. We assessed HROoL (Short Form 36), hearing loss, and tinnitus using questionnaires. We used multivariable linear regression to examine associations between these two auditory complications and HRQoL adjusting for socio-demographic and clinical factors. Our study population consisted of 6,318 CCS (53% female; median age at cancer diagnosis 9 years interquartile range [IQR] 5–13 years) with median age at survey of 31 years (IQR 28–35 years). Prevalence was 7.5% (confidence interval [CI]: 6.9–8.2) for hearing loss and 7.6% (CI: 6.4–9.0) for tinnitus. CCS with hearing loss had impaired physical (coefficient [coef.] -4.3, CI: -7.0 to -1.6) and mental (coef. -3.2, CI: -5.5 to -0.8) HRQoL when compared with CCS with normal hearing. Tinnitus was also associated with impaired physical (coef. -8.2, CI: -11.8 to -4.7) and mental (coef. -5.9, CI: -8.8 to -3.1) HRQoL. We observed the lowest HRQoL among CCS with both hearing loss and tinnitus. Our findings indicate timely treatment of hearing loss and tinnitus may contribute to quality of life of survivors.

INTRODUCTION

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

Cancer treatment can cause auditory complications, such as hearing loss and tinnitus.^{1,2} In recent surveys, childhood cancer survivors (CCS) reported more hearing loss and tinnitus when compared with their siblings.^{3,4} Ototoxic cancer treatments include platinum-based chemotherapy, cranial radiotherapy (CRT), and surgeries involving the auditory system. ^{1,4,5} Other suspected ototoxic treatments are concomitant medications such as aminoglycosides or loop diuretics, hematopoietic stem cell transplantation (HSCT), or the neurotoxic vinca alkaloid vincristine.⁵⁻⁷ Hearing loss and tinnitus lead to a wide range of educational and psychosocial problems such as learning difficulties and emotional distress among CCS and the general population.⁸⁻¹¹ The overall burden of auditory complications ultimately affects health-related quality of life (HRQoL) of CCS. 12-14 Only a few studies have investigated auditory complications and how they affect HRQoL among CCS. 12-14 Previous studies with small sample sizes and heterogeneous inclusion criteria make comparisons between studies difficult since findings can only be extrapolated to the overall CCS population to a limited extent. The association of tinnitus with HRQoL among CCS remains unknown. Several studies examined the prevalence of hearing loss among CCS treated with cisplatin or CRT, yet studies of the overall population—and studies investigating tinnitus—are scarce.^{3, 4, 15, 16} We thus combined harmonized data from four European countries into a large cohort of CCS to describe the prevalence of hearing loss and tinnitus and investigate their association with HROoL.

METHODS

Study population

PanCareLIFE (PCL) is a European-based study on late effects among CCS. It focuses on hearing loss, fertility problems, and quality of life. ^{17, 18} For the current study, we included CCS from Switzerland (CH), Czech Republic (CZ), Germany (DE), and France (FR). The study population included national or regional cohorts of CCS 1) diagnosed with cancer according to the International Classification of Childhood Cancer (ICCC-3), 3rd edition, ¹⁹ or Langerhans cell histiocytosis; 2) aged ≤18 years at time of cancer diagnosis; 3) survived ≥5 years after cancer diagnosis; 4) were off treatment for cancer at time of study; 5) aged 25-44 years when they received the questionnaire. To make data comparable between countries, we restricted our analysis to CCS ≥25 years and <45 years because data for CCS younger than 25 years were unavailable for the German cohort and data for CCS older than 45 years were unavailable for the French cohort. Details about study design, recruitment of participants, country-specific exclusion criteria, and characteristics of different cohorts were published in a separate study protocol. ¹⁷

Study procedure

Each country sent questionnaires to their respective regional or national cohorts between 2005 and 2017.¹⁷ The questionnaires were sent by mail except in CZ where clinic staff distributed them during follow-up visits to former patients. The questionnaire included questions about HRQoL, hearing, socio-demographic characteristics, and lifestyle behavior. Non-responders were reminded to complete the questionnaire.¹⁷ Clinical information on

cancer diagnosis and treatment was extracted from medical records by each participating country.

Assessment of HRQoL

We assessed HRQoL with the Short-Form 36 (SF-36) questionnaire.²⁰ The SF-36 is a widely used instrument; several studies used it to determine HRQoL among CCS.^{12, 21-24} The questionnaire includes 36 items covering different aspects of physical and mental health aggregated into eight health domains: physical functioning (PF, 10 items), role-limitations due to physical problems (RP, 4 items), bodily pain (BP, 2 items), general health (GH, 5 items), vitality (VT, 4 items), social functioning (SF, 2 items), role-limitations due to emotional problems (RE, 3 items) and mental health (MH, 5 items).^{20, 25} These health domains are further collapsed into summary scores that reflect overall physical and mental health: physical component summary (PCS) and mental component summary (MCS). We converted all raw scores into T-scores ranging from 0–100 for each health domain. A higher score indicates better HRQoL. The T-scores were further transformed according to reference data from the German norm population stratified for age and sex (mean=50, SD=10).^{17, 26}

Auditory complications

We defined self-reported hearing loss (yes, no) and tinnitus (yes, no) as our main determinants of interest for impaired HRQoL. Participating country questionnaires contained slightly different worded questions on hearing (Supplement Table S1). The central PCL data center in Mainz (Germany) aggregated data and harmonized variables between participating countries in 2017.¹⁷ Data on tinnitus (yes, no) were unavailable for the German cohort; thus, we excluded German data for analyses involving tinnitus. We coded missing answers for

hearing loss (<1%) and tinnitus (5%) as normal hearing and without tinnitus. We assumed that CCS with hearing loss or tinnitus would be more likely to answer the question than not when compared with CCS without auditory complications.

Clinical and socio-demographic information

Based on previous study findings, we collected clinical and socio-demographic factors possibly associated with HRQoL among CCS: sex (female, male); age at survey; migration background (yes, no); education (primary, secondary, tertiary); occupational status (employed, unemployed); living with a partner (yes, no); currently smoking tobacco (yes, no); drinking >1 alcoholic beverage per week (yes, no); body mass index (BMI); cancer diagnosis according to ICCC-3¹⁹; age at diagnosis; history of relapse (yes, no); surgery (yes, no); chemotherapy (yes, no); radiotherapy (yes, no); HSCT (yes, no). 12, 21, 23, 27 Respondents self-reported age at survey, migration background, education, occupational status, living with a partner, tobacco smoking status, alcohol consumption, and BMI variables. 17 Demographic, cancer-related, and treatment information were extracted from participating institution medical records or corresponding cancer registries. 17

Statistical analysis

We used *t*-tests and fitted multivariable linear regression models to investigate possible associations of hearing loss or tinnitus with HRQoL. First, we examined whether mean scores on SF-36 health domains and PCS and MCS scores differed between CCS with and without auditory complications. We then fitted multivariable linear regression models to investigate whether any possible association of hearing loss or tinnitus with health domains and PCS and MCS scores were explained by clinical or socio-demographic factors. We chose linear

perpetuity.
It is made available under a CC-BY 4.0 International license.

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

regression because HRQoL outcome variables are continuous and binary categorizations of HROoL measured by SF-36 is without consensus in the literature. To mitigate effects of sample imbalances between countries, we standardized cohorts from CZ, DE, and FR according to age at survey and sex variables. Because of the balanced distribution across all age groups and genders, we used the CH cohort as the reference population to calculate appropriate weights. Based on the conceptual framework of directed acyclic graphs (Supplement Figure S1), ²⁸ we adjusted our models for the following co-variables: age at survey (continuous in years); age at cancer diagnosis (continuous in years); type of cancer (categorical according ICCC-3); history of relapse (yes, no); surgery (yes, no); chemotherapy (yes, no); radiotherapy (yes, no); and HSCT (yes, no). We decided to include country of data provider to adjust for country-specific differences in recruitment of study participants and audiological monitoring. ^{17, 29, 30} We calculated global p-values using the Wald test. Since we hypothesized the burden of auditory complications may be largest when both tinnitus and hearing loss are present,³¹ we performed a sub-analysis to further investigate a potential causal relationship between auditory complications and HRQoL. We coded auditory complications as either 1) no auditory complications; 2) hearing loss only; 3) tinnitus only; or 4) hearing loss and tinnitus.

We used Stata version 16.1 (StataCorp LP, Austin, Texas) for all analyses.

RESULTS

162

163

172

Characteristics of study population

164 In total, 6,318 CCS were available for our analysis. Of the 6,318 CCS, most were from DE (n = 4,650; 74%); 822 (13%) from CH; 592 (9%) from CZ; and 254 (4%) from FR (Table 1). 165 166 Our study population included 3,326 (53%) females and 2,992 (47%) males with median age of 31 (interquartile range [IQR] 28-35 years) at survey, median age 9 (IQR 5-13 years) at 167 168 cancer diagnosis, and median 23 years (IOR 19-28) since cancer diagnosis. Leukemias (n = 169 2,033;32%), lymphomas (n = 1,466; 23%), and central nervous system (CNS) tumors (n = 170 892; 14%) were most common cancer diagnoses. CCS received cancer treatment by surgery 171 (2,580; 41%); chemotherapy (5,070; 80%); and radiotherapy (3,092; 49%).

Prevalence of auditory complications after childhood cancer

Of participating CCS, 7.5% (476/6.318; CI: 6.9-8.2) reported hearing loss. Data on tinnitus 173 174 was available for the cohorts from CH, CZ, and FR resulting in a combined cohort of 1,668 CCS. Of those, 7.6% (127/1,668; CI: 6.4-9.0) reported tinnitus. Among CCS with tinnitus (n= 175 176 127), 45 (35%) also reported hearing loss. CCS diagnosed with CNS tumors, neuroblastoma, 177 hepatic tumors, malignant bone tumors, soft tissue sarcomas, germ cell tumors, and epithelial 178 neoplasms reported hearing loss more often than CCS diagnosed with leukemia (all p <179 0.001) (Figure 1). CCS of hepatic tumors had the highest prevalence of hearing loss (8/28; 180 28.6%, CI: 13.2-48.7) followed by malignant bone tumors (91/378; 24.1%, CI: 19.8-28.7) and 181 CNS tumors (130/892; 14.6%, CI: 12.3-17.1). Tinnitus prevalence was highest among CCS 182 diagnosed with malignant bone tumors (16/103; 15.5%, CI: 9.1-24.0) and CNS tumors 183 (33/255; 12.9%, CI: 9.1-17.7) (Figure 2).

Association of auditory complications with HRQoL

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

CCS with hearing loss had lower HRQoL mean scores than CCS with normal hearing (all differences with p<0.001) (Figure 3A). Looking at SF-36 summary scores, CCS with hearing loss scored 45.3 in overall physical (PCS) and 46.0 in overall mental (MCS) HRQoL. In comparison, CCS with normal hearing had 51.7 for PCS and 50.0 for MCS scores. Among the eight health domains, we observed the largest mean differences between CCS with and without hearing loss in physical functioning (40.6 vs. 48.3), general health (45.1 vs. 50.9), and social functioning (43.0 vs. 48.2). CCS with tinnitus scored lower than CCS without tinnitus in all health domains and PCS (42.7 vs. 52.2) and MCS (43.1 vs. 49.9) summary scores (all differences with p<0.001) (Figure 3B). The largest mean differences between CCS with and without tinnitus were again in physical functioning (40.2 vs. 48.9), general health (41.6 vs. 51.0), and social functioning (39.7 vs. 48.3). In the multivariable linear regression, hearing loss remained associated with lower HRQoL scores after adjusting for socio-demographic and cancer-related factors (Table 2). For PCS, coef. were -4.3 (CI: -7.0 to -1.6) among those with hearing loss and -3.2 (CI: -5.5 to -0.8) for MCS. On average, overall physical or mental HROoL was reduced by 4.3 or 3.2 points for CCS with hearing loss compared with CCS with normal hearing. The association was strongest for general health, followed by physical functioning, vitality, and social functioning (coef. ranging from -4.6 to -3.8, p<0.05) (Table 2). We observed borderline or no associations of hearing loss in role physical and role emotional.

Tinnitus also remained associated with lower HRQoL scores in multivariable linear regression (Table 2). The effects of tinnitus on PCS (coef. -8.2, CI: -11.8 to -4.7) and MCS (coef. -5.9, CI: -8.8 to -3.1) were greater compared with the effects of hearing loss (coef. of -4.3 for PCS and -3.2 for MCS). We found the strongest effect of tinnitus on vitality (coef. -8.4, CI: -11.3 to -5.6), general health (coef. -8.3, CI: -11.4 to -5.3), and social functioning (coef. -7.9, CI: -11.0 to -4.7) (all p < 0.001).

We found CCS with both tinnitus and hearing loss had lower overall physical and mental HRQoL compared with CCS with hearing loss alone (coef. -14.5 vs. -0.6 for PCS and coef. -5.0 vs. -2.9 for MCS) (Table 3). When compared with tinnitus alone, the effect of hearing loss and additional tinnitus was also larger for overall physical HRQoL (coef. -5.4 vs. -14.5 for PCS), yet similar for overall mental HRQoL (coef. -6.8 vs. -5.0 for MCS).

DISCUSSION

We found the prevalence of auditory complications varied between cancer diagnoses and the highest prevalence of hearing loss and tinnitus among survivors of CNS and malignant bone tumors. HRQoL was lower among CCS with auditory complications than for those with normal hearing. Hearing loss and tinnitus were strongly associated with physical functioning, vitality, general health, and social functioning. We observed lower HRQoL among CCS with hearing loss and additional tinnitus compared with CCS with hearing loss alone.

Strengths and limitations

Since our study is the largest cohort of CCS to examine auditory complications and their association with HRQoL, it results in high statistical power and good representativeness because it combined data from population-based and regional well-defined cohorts. Tinnitus is more frequent among CCS compared with the general population,² yet its association with HRQoL among CCS was unknown. We included CCS with all possible cancer treatments, not only those exposed to ototoxic treatments such as platinum-based chemotherapy or CRT, which allowed assessing the burden of auditory complications among the overall population of CCS.³2 We applied SF-36—an established and validated instrument widely used in previous studies—to measure HRQoL among CCS, which allows comparing our data with other studies.²¹-²³, ²², ³³, ³⁴ Data from participating countries were collected centrally and harmonized before merging to avoid data management errors.¹¹ However, our study results might still be influenced by study design differences of participating countries, leading to potential selection bias. For example, FR did not contact CCS of leukemias, and—similar to DE—sent questionnaires later (≥10 years) than CH and CZ (both ≥5 years) after cancer

diagnosis. ¹⁷ Considering the French cohort represents only 4% of the total study population, we assume that selection based on cancer diagnosis did not result in a major bias in our findings. Additionally, time since diagnosis was investigated in two larger population-based studies showing either no or minor effects on HRQoL among CCS. ^{23, 27} Other limitations relate to the main exposures of interest; hearing loss and tinnitus. Since auditory complications were assessed by questionnaire and dependent on severity, underreporting is possible. For instance, CCS with severe hearing loss possibly received better audiologic care and recall it better than CCS with mild high-frequency hearing loss who are unaware of it. ³⁵ Additionally, SF-36 does not specifically measure HRQoL related to hearing and may not capture life situations affected by auditory complications,

Comparison with previous studies

Among our study population, 7.5% of CCS reported hearing loss. We observed particularly high prevalence among survivors of hepatoblastoma, CNS tumors, and malignant bone tumors—an expected finding from higher cisplatin or CRT use compared with other cancer treatment regimes.^{5,7} Larger studies on hearing loss prevalence among CCS mostly focused on high-risk populations treated with platinum-based chemotherapy or CRT.⁵⁻⁷ Two population-based studies from Switzerland (Swiss Childhood Cancer Survivor Study; SCCSS) and the United States (Childhood Cancer Survivor Study; CCSS) determined the prevalence of hearing loss among the overall CCS population with questionnaires.^{3, 16} The Swiss population in our cohort overlaps with the study population of the SCCSS.^{3, 17, 36} Therefore, we only compared our data with the CCSS study.¹⁶ Whelan and colleagues found a prevalence of self-reported hearing loss of 5%, which is slightly lower than what we found (7.5%).¹⁶ They included CCS diagnosed in earlier years (1970-1986) compared with our study

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

(1974-2009), which possibly explains the difference. Considering cisplatin was first approved in 1978 for adult cancer treatment, it is possible a higher proportion of CCS in our cohort were treated with ototoxic platinum-based chemotherapy, as Weiss and colleagues also discuss in their SCCSS study.^{3, 37} The prevalence of tinnitus was 7.6% among our study population. CCS diagnosed with CNS tumors or malignant bone tumors had a three to four times higher prevalence compared with survivors of leukemias. The higher prevalence is possibly explained by previously identified risk factors for tinnitus among CCS, such as exposure to cisplatin, CRT, and CNS surgeries. In Meijer and colleagues' systematic review, the prevalence of tinnitus ranged from 3-17%.² They also recently published a population-based study where they estimated the prevalence of tinnitus to be 9.5% among CCS compared with 3.7% for siblings.⁴ Their findings are consistent with our study. Audiological complications were associated with lower HRQoL, particularly with decreased physical functioning, general health, vitality, and social functioning. Physical functioning reflects limitations in physical activities, such as difficulties walking a mile or exercising vigorously due to health problems.²⁰ In a SCCSS study, physical well-being was lower among younger CCS with hearing loss than for CCS with normal hearing. ¹² General health reflects current and future health perceptions; for example, how people perceive their health when compared with peers or whether their health deteriorates in the future.²⁰ General health was also heavily impaired among CCS when compared with siblings or the general population in previous studies.^{23,27} The SF-36 assesses vitality with questions such as whether people feel full of energy or tired and worn out.²⁰ Previous studies of the general population showed—depending on severity—patients with tinnitus experience comorbidities, such as

sleep disturbance, fatigue, and depression. ^{10, 11, 38} Hearing loss possibly leads to feelings of fatigue from long periods of effortful listening. ³⁹⁻⁴¹ Impaired social functioning refers to limitations in social activities, such as visiting family and friends, due to physical or emotional health problems. ²⁰ CCS with hearing loss reported psychosocial difficulties and communication problems in previous studies examining the impact of hearing loss on HRQoL. ¹²⁻¹⁴ Yet, a direct comparison with our study remains difficult because they only included children and adolescents—a study population whose social behavior differs from our adult study population (median age 31 at survey). Data from adult CCS participating in the St. Jude Lifetime Cohort Study showed treatment-related hearing loss associated with reduced social attainment, which possibly relates to decreased social engagement. ⁴² However, none of these studies investigated the impact of tinnitus on social behavior and attainment.

Causality between auditory complications and HRQoL

The observed association of lower vitality and social functioning possibly relates to educational and psychosocial problems caused by auditory complications. ^{8, 10, 11, 13} Other chronic health problems, such as musculoskeletal or neurological, also affect HRQoL. ²⁷ In our study, we could not adjust for other chronic health problems. Since the risk of auditory complications and other chronic health problems increases with more intensive cancer treatment, unobserved late effects in other organ systems could contribute to lower physical and mental HRQoL (Supplement Figure S1). ^{4, 5, 7, 43, 44} However, we observed hearing loss with additional tinnitus reduces HRQoL more than hearing loss alone. Since we assumed the burden on daily life is greater when CCS experience both hearing loss and tinnitus, it possibly indicates a causal relationship. ³¹ Interestingly, tinnitus alone also had a greater impact on HRQoL than hearing loss alone. Since data are self-reported and tinnitus is probably

underreported in our study, further research using objective hearing tests and validated instruments to assess tinnitus are important to understand its impact on CCS. ^{30, 45}

Conclusion

Our study showed hearing loss and tinnitus strongly affected HRQoL among CCS—particularly reduced HRQoL among survivors with both, hearing loss and tinnitus. Our findings support current guideline recommendations for timely referrals to audiologists for tinnitus symptoms and optimized treatment of hearing loss and tinnitus since both affect HRQoL.³⁰

AUTHORS CONTRIBUTIONS

SST and KB are the first authors of this paper and both contributed substantially to this work. SST prepared the final data set, wrote the manuscript, performed the data analysis and interpretated the results. KB coordinated the study, contributed to the design, implementation, data collection and harmonization, data preparation, reviewed the manuscript, and commented on data analysis and interpretation. DG and JB were part of the PanCareLIFE coordination team and contributed to the implementation and coordination of the study; they also supervised collection, and harmonization and maintenance of data. TL and AaZD contributed to the study implementation and to data harmonization and they provided their medical expertise for data analysis and interpretation. RK, AW, TK, JK, CB conducted the study in the different countries and contributed to data collection and harmonization. AW was involved in the study design. GC supervised the design, implementation and coordination of the study, and contributed to data collection, harmonization and analysis. GS and CK are senior authors of the study; they were involved in the study design and implementation, in

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

collection, harmonization, and maintenance of data, they supervised analysis and interpretation of data and reviewed the manuscript. All co-authors provided feedback on the manuscript and approved its final version. **ACKNOWLEDGMENTS** We thank all survivors of childhood and adolescent cancers and their families for their participation in our study. PanCareLIFE (Grant no. 602030) is a collaborative project in the 7th Framework Program of the European Union. Project partners are Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Germany (PD Dr P Kaatsch, Dr D Grabow); Boyne Research Institute, Drogheda, Ireland (Dr J Byrne, Ms H Campbell); Pintail Ltd., Dublin, Ireland (Mr C Clissmann, Dr K O'Brien); Academisch Medisch Centrum bij de Universiteit van Amsterdam, the Netherlands (Prof Dr LCM Kremer); Universität zu Lübeck, Germany (Prof T Langer); Stichting VU-VUMC, Amsterdam, the Netherlands (Dr E van Dulmen-den Broeder, Dr MH van den Berg); Erasmus Universitair Medisch Centrum, Rotterdam, the Netherlands; and Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands (Prof Dr MM van den Heuvel-Eibrink); Charité-Universitätsmedizin Berlin, Germany (Prof Dr A Borgmann-Staudt); Westfälische Wilhelms-Universität Münster, Germany (Prof Dr A am Zehnhoff-Dinnesen); Universität Bern, Switzerland (Prof Dr CE Kuehni); Istituto Giannina Gaslini, Genoa, Italy (Dr R Haupt); Fakultni nemocnice Brno, Czech Republic (Dr T Kepak); Centre Hospitalier Universitaire Saint-Étienne, Saint-Étienne, France (Dr C Berger); Kraeftens Bekaempelse, Copenhagen, Denmark (Dr JF Winther); Fakultni

nemocnice v Motole, Prague, the Czech Republic (Dr J Kruseova); Universitaetsklinikum

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

Bonn, Bonn, Germany (Dr G Calaminus, K Baust); and University Hospital Essen, Essen, Germany (Prof U Dirksen). The EU Commission takes no responsibility for any use made of the information set out. In Switzerland, we thank the Swiss Childhood Cancer Survivor Study team, the Swiss Paediatric Oncology Group data managers, and the Swiss Childhood Cancer Registry study team. We also thank Marcel Zwahlen for statistical advice. We thank the editorial service of the Institute of Social and Preventive Medicine at the University of Bern for the editorial suggestions. In Czech Republic, at the University Hospital of Brno we thank the team of collaborators from the Children's Hospital in Brno, Masaryk University in Brno, especially Katerina Kepakova, and Brno survivors' association Together Toward a Smile: H Hrstková, V Bajčiová, D Hošnová, Z Kuttnerová, M Blanářová, R Mazúr, I Mikulec, E Bučková, L Červinková, E Bařinová, I Krupková, E Novotná, P Chloupková, Z Wimmerová, L Štrublová, and many other external collaborators and supporters. At the University Hospital of Prague LTFU Care Registry, the authors thank the team of the Prague Childhood Cancer Survivor Study: Aleš Lukš, P Keslová, M Ganevová, V Reichlová, J Bašeová, L Nováková, M Douchová, and M Čepelová. In France, we thank the team of the long-term follow-up study (SALTO): Faure-Conter (Lyon), N Corradini (Lyon), D Plantaz (Grenoble), E Tarral (Grenoble), I Durieu (Lyon), I Guichard (Saint-Étienne), L Casagranda and F Odier (Saint-Étienne), N Gauthier (Lyon), P Métral (Lyon), M Mercier (Lyon), S Billet (Grenoble), C Celette (Grenoble), I Schiff (Grenoble), and A Loubier (Saint-Étienne).

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

In Germany, we thank the team of the Clinic of Phoniatrics and Pedaudiology at the University Hospital in Münster and the VIVE group and members of the GCCR: U Creutzig (Hannover), T Langer (Lübeck), J Dobke (Berlin), I Jung (Mainz), I Kerenyi (Mainz), C Teske (Bonn), and M Zimmermann (Hannover). In Germany, they also thank the team at GCCR in its role as central data center for PanCareLIFE (Peter Kaatsch, Claudia Spix, Melanie Kaiser, Claudia Bremensdorfer). Our project received funding from the European Union's Seventh Framework Program for research, technological development, and demonstration under Grant no. 602030. In Switzerland, our project received funding from the Swiss Cancer League (Grant no. KLS-3412-02-2014, KLS-3886-02-2016, and HSR-4951-11-2019), the Swiss Cancer Research Foundation (Grant no. KFS-4157-02-2017), the Bernese Cancer League, Kinderkrebshilfe Schweiz, Kinderkrebs Schweiz, and the CANSEARCH Foundation (https://cansearch.ch/en/). The work of the SCCR was supported by the Swiss Pediatric Oncology Group, Schweizerische Konferenz der kantonalen Gesundheitsdirektorinnen und direktoren, the Swiss Cancer Research, Kinderkrebshilfe Schweiz, Bundesamt für Gesundheit, National Institute for Epidemiology and Cancer Registration, and Celgene. In the Czech Republic, our study received funding from the University Hospital of Brno from the Ministry of Education, Youth and Sports of the Czech Republic, under Grant no. 7E13061 and the University Hospital of Prague from the foundation Národ dětem. In France, our study received funding from The Wyeth Foundation, the French National Institute of Cancer (INCa), and the French League against Cancer.

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

In Germany, our study received funding from the German Cancer Aid (Grant No. 110298). Data for this subproject were provided by University of Bern, Switzerland (Prof CE Kuehni); Fakultni nemocnice Brno, Czech Republic (Dr T Kepak); Centre Hospitalier Universitaire Saint-Étienne, France (Dr C Berger); Fakultni nemocnice v Motole, Prague, Czech Republic (Dr J Kruseova); and Universitaetsklinikum Bonn, Bonn, Germany (Dr G Calaminus). Prof Dr NW Paul at the University of Mainz and Prof Dr Lisbeth E Knudsen from the University of Copenhagen provided independent ethics advice CONFLICT OF INTEREST STATEMENT The authors declare that there is no conflict of intere DATA AVAILABILITY STATEMENT The data that support the information of this manuscript were accessed on secured servers of the Institute of Social and Preventive Medicine at the University of Bern. Individual-level sensitive data can only be made available for researchers who fulfil the respective legal requirements. All data requests should be communicated to the corresponding author. ETHICS STATEMENT PanCareLIFE is a multinational collaborative research project that has harmonized and combined data from regional and national cohorts across Europe. Data collection and analysis for each cohort was approved by the responsible ethics committee in each participating

414

415

416

417

418

419

420

421

422 423

424

425

426

427

428

429

430

431

432 433

434

435

436

437

438

439

440

441

442

country. For Germany this is the Ethics Committee of the Medical Association of Westphalia-Lippe and the Medical faculty of the Westphalian Wilhelms University (2012-530-f-S), for Switzerland the Cantonal Ethics Committee of the Canton of Bern (KEK-BE: 166/2014; 2021-01462), for the Czech Republic the Ethics Committee for Multi-Centric Clinical Trials of the University Hospital Motol (EK-1723/13) and the Multi-Centric Ethics Committee of the University Hospital Brno (approval date: 2014/10/22), and for France the Personal Protection Committee South East 1 (CPP: 2015-23). REFERENCES 1. Landier W. Ototoxicity and cancer therapy. Cancer 2016;122:1647-58. 2. Meijer AJM, Clemens E, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM. Tinnitus during and after childhood cancer: A systematic review. Critical reviews in oncology/hematology 2019;135:1-7. 3. Weiss A, Sommer G, Kasteler R, Scheinemann K, Grotzer M, Kompis M, Kuehni CE. Long-term auditory complications after childhood cancer: A report from the Swiss Childhood Cancer Survivor Study. Pediatric blood & cancer 2017;64:364-73. 4. Meijer AJM, Fiocco MF, Janssens GO, Clemens E, Tissing WJE, Loonen JJ, van Dulmen-den Broeder E, de Vries ACH, Bresters D, Versluys B, Ronckers CM, Kremer LCM, et al. Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a Dutch LATER questionnaire study. Neuro-oncology advances 2020;2:vdaa122. 5. Strebel S, Mader L, Sláma T, Waespe N, Weiss A, Parfitt R, Am Zehnhoff-Dinnesen A, Kompis M, von der Weid NX, Ansari M, Kuehni CE. Severity of hearing loss after platinum chemotherapy in childhood cancer survivors. Pediatric blood & cancer 2022;69:e29755. 6. Clemens E, de Vries AC, Pluijm SF, Am Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, van Dulmen-den Broeder E, Bresters D, Versluys B, Kremer LC, van der Pal HJ, van Grotel M, et al. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study. European journal of cancer (Oxford, England: 1990) 2016;69:77-85. 7. Moke DJ, Luo C, Millstein J, Knight KR, Rassekh SR, Brooks B, Ross CJD, Wright M, Mena V, Rushing T, Esbenshade AJ, Carleton BC, et al. Prevalence and risk factors for

443 cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional 444 North American cohort study. The Lancet. Child & adolescent health 2021;5:274-83.

- 445 8. Bass JK, Liu W, Banerjee P, Brinkman TM, Mulrooney DA, Gajjar A, Pappo AS,
- 446 Merchant TE, Armstrong GT, Srivastava D, Robison LL, Hudson MM, et al. Association of
- 447 Hearing Impairment With Neurocognition in Survivors of Childhood Cancer. JAMA
- 448 oncology 2020;6:1363-71.
- 449 9. Orgel E, O'Neil SH, Kayser K, Smith B, Softley TL, Sherman-Bien S, Counts PA,
- 450 Murphy D, Dhall G, Freyer DR. Effect of Sensorineural Hearing Loss on Neurocognitive
- 451 Functioning in Pediatric Brain Tumor Survivors. Pediatric blood & cancer 2016;63:527-34.
- 452 10. Langguth B. A review of tinnitus symptoms beyond 'ringing in the ears': a call to 453 action. Current medical research and opinion 2011;27:1635-43.
- 454 11. Bhatt JM, Bhattacharyya N, Lin HW. Relationships between tinnitus and the 455 prevalence of anxiety and depression. The Laryngoscope 2017;127:466-69.
- 12. Weiss A, Sommer G, Schindera C, Wengenroth L, Karow A, Diezi M, Michel G, 456
- 457 Kuehni CE. Hearing loss and quality of life in survivors of paediatric CNS tumours and other
- 458 cancers. Quality of life research: an international journal of quality of life aspects of
- 459 treatment, care and rehabilitation 2019;28:515-21.
- 13. Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML. Hearing 460 461 loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report
- 462 from the Children's Oncology Group. Pediatrics 2007;120:e1229-36.
- 463 14. Rajput K, Edwards L, Brock P, Abiodun A, Simpkin P, Al-Malky G. Ototoxicity-464 induced hearing loss and quality of life in survivors of paediatric cancer. International journal 465 of pediatric otorhinolaryngology 2020;138:110401.
- 466 15. van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss after 467 treatment for childhood cancer. The Cochrane database of systematic reviews
- 2016;2016:Cd010181. 468
- 469 16. Whelan K, Stratton K, Kawashima T, Leisenring W, Hayashi S, Waterbor J, Blatt
- 470 J, Sklar CA, Packer R, Mitby P, Robison LL, Mertens AC. Auditory complications in
- 471 childhood cancer survivors: a report from the childhood cancer survivor study. Pediatric blood
- 472 & cancer 2011;57:126-34.
- 473 17. Calaminus G, Baust K, Berger C, Byrne J, Binder H, Casagranda L, Grabow D,
- Grootenhuis M, Kaatsch P, Kaiser M, Kepak T, Kepáková K, et al. Health-Related Quality of 474
- 475 Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE.
- 476 JMIR research protocols 2021;10:e21851.

perpetuity.

It is made available under a CC-BY 4.0 International license .

477

478

479

480

481

482

483

484

485

486

487 488

489

490

491 492

493

494

495

496

497

498

499

500

501

502

503

504

505506

507

508

509

510

511

512

18. Byrne J, Grabow D, Campbell H, O'Brien K, Bielack S, Am Zehnhoff-Dinnesen A, Calaminus G, Kremer L, Langer T, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, Baust K, et al. PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents. European journal of cancer (Oxford, England: 1990) 2018;103:227-37. 19. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer 2005;103:1457-67. 20. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical care 1992;30:473-83. 21. Reulen RC, Winter DL, Lancashire ER, Zeegers MP, Jenney ME, Walters SJ, Jenkinson C, Hawkins MM. Health-status of adult survivors of childhood cancer: a largescale population-based study from the British Childhood Cancer Survivor Study. International journal of cancer 2007;121:633-40. 22. Reulen RC, Zeegers MP, Jenkinson C, Lancashire ER, Winter DL, Jenney ME, Hawkins MM. The use of the SF-36 questionnaire in adult survivors of childhood cancer: evaluation of data quality, score reliability, and scaling assumptions. Health and quality of life outcomes 2006;4:77. 23. van Erp LME, Maurice-Stam H, Kremer LCM, Tissing WJE, van der Pal HJH, de Vries ACH, van den Heuvel-Eibrink MM, Versluys BAB, Loonen JJ, Bresters D, Louwerens M, van der Heiden-van der Loo M, et al. Health-related quality of life in Dutch adult survivors of childhood cancer: A nation-wide cohort study. European journal of cancer (Oxford, England: 1990) 2021;152:204-14. 24. Penson A, Walraven I, Bronkhorst E, Maurice-Stam H, Grootenhuis MA, Van der Heiden-van der Loo M, Tissing WJE, Van der Pal HJH, De Vries ACH, Bresters D, Ronckers C, Van den Heuvel MM, et al. The Impact of Cancer-Related Fatigue on HRQOL in Survivors of Childhood Cancer: A DCCSS LATER Study. Cancers 2022;14. 25. Roser K, Mader L, Baenziger J, Sommer G, Kuehni CE, Michel G. Health-related quality of life in Switzerland: normative data for the SF-36v2 questionnaire. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation 2019;28:1963-77. 26. Ellert U, Bellach BM. [The SF-36 in the Federal Health Survey--description of a current normal sample]. Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)) 1999;61 Spec No:S184-90. 27. Rueegg CS, Gianinazzi ME, Rischewski J, Beck Popovic M, von der Weid NX,

Michel G, Kuehni CE. Health-related quality of life in survivors of childhood cancer: the role

513 of chronic health problems. Journal of cancer survivorship: research and practice 2013;7:511-514 22. 515 28. Hernán MA, Hernández-Díaz S, Werler MM, Mitchell AA. Causal knowledge as a 516 prerequisite for confounding evaluation: an application to birth defects epidemiology. 517 American journal of epidemiology 2002;155:176-84. 518 29. Weiss A, Kuonen R, Brockmeier H, Grotzer M, Candreia C, Maire R, Senn P, 519 Stieger C, Rosenfeld J, Veraguth D, Kompis M, Scheinemann K, et al. Audiological 520 monitoring in Swiss childhood cancer patients. Pediatric blood & cancer 2018;65. 521 30. Clemens E, van den Heuvel-Eibrink MM, Mulder RL, Kremer LCM, Hudson MM, 522 Skinner R, Constine LS, Bass JK, Kuehni CE, Langer T, van Dalen EC, Bardi E, et al. 523 Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult 524 cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline 525 Harmonization Group in collaboration with the PanCare Consortium. The Lancet. Oncology 526 2019;20:e29-e41. 527 31. Joo YH, Han KD, Park KH. Association of Hearing Loss and Tinnitus with 528 Health-Related Quality of Life: The Korea National Health and Nutrition Examination 529 Survey. PloS one 2015;10:e0131247. 32. Strebel S, Waespe N, Kuehni CE. Hearing loss in childhood cancer survivors. The 530 531 Lancet. Child & adolescent health 2021;5:e17. 33. Nathan PC, Ness KK, Greenberg ML, Hudson M, Wolden S, Davidoff A, 532 533 Laverdiere C, Mertens A, Whitton J, Robison LL, Zeltzer L, Gurney JG. Health-related 534 quality of life in adult survivors of childhood Wilms tumor or neuroblastoma: A report from 535 the childhood cancer survivor study. Pediatric blood & cancer 2007;49:704-15. 536 34. Zeltzer LK, Lu Q, Leisenring W, Tsao JC, Recklitis C, Armstrong G, Mertens AC, 537 Robison LL, Ness KK. Psychosocial outcomes and health-related quality of life in adult 538 childhood cancer survivors: a report from the childhood cancer survivor study. Cancer 539 epidemiology, biomarkers & prevention: a publication of the American Association for 540 Cancer Research, cosponsored by the American Society of Preventive Oncology 541 2008;17:435-46. 542 35. Weiss A, Sommer G, Kuonen R, Scheinemann K, Grotzer M, Kompis M, Kuehni 543 CE. Validation of questionnaire-reported hearing with medical records: A report from the 544 Swiss Childhood Cancer Survivor Study. PloS one 2017;12:e0174479. 545 36. Kuehni CE, Rueegg CS, Michel G, Rebholz CE, Strippoli MP, Niggli FK, Egger 546 M, von der Weid NX. Cohort profile: the Swiss childhood cancer survivor study. International

547

journal of epidemiology 2012;41:1553-64.

549

550

551

552

553

554

555

556

557

558 559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

37. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature reviews. Cancer 2007;7:573-84. 38. Izuhara K, Wada K, Nakamura K, Tamai Y, Tsuji M, Ito Y, Nagata C. Association between tinnitus and sleep disorders in the general Japanese population. The Annals of otology, rhinology, and laryngology 2013;122:701-6. 39. Bess FH, Hornsby BW. Commentary: listening can be exhausting--fatigue in children and adults with hearing loss. Ear and hearing 2014;35:592-9. 40. Davis H, Schlundt D, Bonnet K, Camarata S, Bess FH, Hornsby B. Understanding Listening-Related Fatigue: Perspectives of Adults with Hearing Loss. International journal of audiology 2021;60:458-68. 41. Alhanbali S, Dawes P, Lloyd S, Munro KJ. Self-Reported Listening-Related Effort and Fatigue in Hearing-Impaired Adults. Ear and hearing 2017;38:e39-e48. 42. Brinkman TM, Bass JK, Li Z, Ness KK, Gajjar A, Pappo AS, Armstrong GT, Merchant TE, Srivastava DK, Robison LL, Hudson MM, Gurney JG. Treatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: Results from the St. Jude Lifetime Cohort Study. Cancer 2015;121:4053-61. 43. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, et al. Chronic health conditions in adult survivors of childhood cancer. The New England journal of medicine 2006;355:1572-82. 44. Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, Chemaitilly W, Ehrhardt MJ, Bass J, Bishop MW, Shelton K, Lu L, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet (London, England) 2017;390:2569-82. 45. Baguley D, McFerran D, Hall D. Tinnitus. Lancet (London, England) 2013;382:1600-7.

perpetuity.

It is made available under a CC-BY 4.0 International license .

LEGENDS

Supplementary Figure S1

Table 1 Demographic and clinical characteristics of study population Table 2 Association of hearing loss and tinnitus with HRQoL from adjusted linear regression Table 3 Association of combined auditory complications on HRQoL from adjusted linear regression Figure 1 Prevalence of self-reported hearing loss at the time of the study Figure 2 Prevalence of self-reported tinnitus at the time of the study Figure 3 Spider chart showing norm-based mean scores for all eight health domains and the two summary scores of the SF-36 comparing CCS with and without auditory complications Questions on auditory complications from the questionnaires of each participating country Supplementary Table S1 translated into English Norm-based mean scores from SF-36 comparing CCS with hearing loss and normal hearing **Supplementary Table S2** Norm-based mean scores from SF-36 comparing CCS with and without tinnitus **Supplementary Table S3**

Directed acyclic graph (DAG)

 TABLE 1
 Demographic and clinical characteristics of study population

| | | <i>J</i> 1 |
|-------------------------------------|--------------|------------|
| | Total cohort | |
| | (N=6,318) | |
| Demographic characteristics | n | (%) |
| Sex | | |
| Male | 2,992 | (47) |
| Female | 3,326 | (53) |
| Age at survey (years) | | |
| 25-29.9 | 2,651 | (42) |
| 30-34.9 | 2,061 | (33) |
| 35-39.9 | 1,074 | (17) |
| 40-44 | 532 | (8) |
| Country of origin | | |
| Germany | 4,650 | (74) |
| Switzerland | 822 | (13) |
| Czech Republic | 592 | (9) |
| France | 254 | (4) |
| Clinical characteristics | n | (%) |
| Age at cancer diagnosis (years) | | |
| 0-4.9 | 1,763 | (28) |
| 5-9.9 | 1,696 | (27) |
| 10-18 | 2,859 | (45) |
| Period of cancer diagnosis | _,== | (10) |
| 1974-1984 | 1,254 | (20) |
| 1985-1994 | 3,488 | (55) |
| 1995-2004 | 1,517 | (24) |
| 2005-2009 | 59 | (1) |
| Time since cancer diagnosis (years) | | |
| 5-14.9 | 592 | (9) |
| 15-24.9 | 3,208 | (51) |
| 25-42 | 2,518 | (40) |
| Cancer diagnosis (ICCC-3) | 2,510 | (10) |
| I Leukemias | 2,033 | (32) |
| II Lymphomas | 1,466 | (23) |
| III CNS tumours | 892 | (14) |
| IV Neuroblastoma | 236 | (4) |
| V Retinoblastoma | 130 | (2) |
| VI Renal tumours | 390 | (6) |
| VII Hepatic tumours | 28 | (<1) |
| VIII Bone tumours | 378 | (6) |
| IX Soft tissue sarcomas | 396 | (6) |
| X Germ cell tumours | 249 | |
| | 80 | (4) |
| XI Epithelial neoplasms & melanomas | | (1) |
| XII Other malignant neoplasms | 40 | (1) |
| Subsequent tumour Yes | 150 | (7) |
| | 458 5.860 | (7) |
| No | 5,860 | (93) |

TABLE 1 Continued.

| | n | (%) |
|-------------------------|-------|------|
| Treatments ^a | | |
| Surgery | | |
| Unknown | 863 | (14) |
| Yes | 2,580 | (41) |
| No | 2,875 | (46) |
| Chemotherapy | | |
| Unknown | 603 | (10) |
| Yes | 5,070 | (80) |
| No | 645 | (10) |
| Radiotherapy | | |
| Unknown | 858 | (14) |
| Yes | 3,092 | (49) |
| No | 2,368 | (37) |
| HSCT | | |
| Unknown | 287 | (5) |
| Yes | 151 | (2) |
| No | 5,880 | (93) |

Abbreviations: ICCC-3, International Classification of Childhood Cancer-Third Edition; CNS, central nervous system; HSCT, hematopoietic stem cell transplantation.

^aEach subject could have had more than one treatment modality.

TABLE 2 Association of hearing loss and tinnitus with HRQoL from adjusted linear regression analysis

| | Adjusted ^a association of hearing loss ^b | | Adjusted ^a association of tinnitus ^c | |
|---------------------------|--|------------|--|------------------|
| Health Domains | Coef. (95%-CI) | $P^{ m d}$ | Coef. (95%-CI) | P^{d} |
| Physical Functioning (PF) | -4.5 (-7.7 to -1.4) | 0.005 | -7.2 (-11.2 to -3.2) | < 0.001 |
| Role Physical (RP) | -2.3 (-4.6 to -0.1) | 0.044 | -5.9 (-8.8 to -2.9) | < 0.001 |
| Role Emotional (RE) | -2.5 (-5.4 to 0.4) | 0.088 | -3.9 (-7.0 to -0.8) | 0.014 |
| Bodily Pain (BP) | -2.6 (-4.4 to -0.8) | 0.004 | -5.3 (-7.6 to -3.0) | <0.001 |
| Mental Health (MH) | -2.8 (-4.7 to -0.8) | 0.005 | -4.2 (-6.9 to -1.6) | 0.002 |
| Vitality (VT) | -3.9 (-6.0 to -1.8) | < 0.001 | -8.4 (-11.3 to -5.6) | <0.001 |
| General Health (GH) | -4.6 (-6.9 to -2.3) | < 0.001 | -8.3 (-11.4 to -5.3) | <0.001 |
| Social Functioning (SF) | -3.8 (-6.3 to -1.3) | 0.003 | -7.9 (-11.0 to -4.7) | < 0.001 |
| Global Summary Scores | Coef. (95%-CI) | $P^{ m d}$ | Coef. (95%-CI) | $P^{ m d}$ |
| PCS | -4.3 (-7.0 to -1.6) | 0.002 | -8.2 (-11.8 to -4.7) | < 0.001 |
| MCS | -3.2 (-5.5 to -0.8) | 0.008 | -5.9 (-8.8 to -3.1) | < 0.001 |

Abbreviations: Coef., estimated beta coefficient from multivariable linear regression; PCS, physical component summary; MCS, mental component summary.

^aAdjusted for: age at survey (continuous, in years); age at cancer diagnosis (continuous, in years); type of cancer diagnosis (according ICCC-3); history of relapse (yes/no); surgery (yes, no); chemotherapy (yes, no); radiotherapy (yes, no); type of cancer diagnosis (according ICCC-3); history of relapse (yes/no); surgery (yes, no); chemotherapy (yes, no); radiotherapy (yes, no); country of data provider.

^bWe included the total cohort for analysis of the association of hearing loss on HRQoL (N=6,318).

^cWe included the cohorts from CH, CZ, and FR for analysis of the association of tinnitus on HRQoL (N=1,668) but excluded the cohort from Germany (n=4,650) because no data on tinnitus was available for the German cohort.

^dP-value calculated from Wald test.

 TABLE 3
 Association of combined auditory complications on HRQoL from adjusted linear regression analysis

| | Adjusted ^a associa combined auditory con | |
|---------------------------|--|---------|
| Health Domains | Coef. (95%-CI) | P^{c} |
| Physical Functioning (PF) | | 0.002 |
| No auditory complications | Reference | |
| Hearing loss only | -0.1 (-3.3 to 3.1) | |
| Tinnitus only | -3.3 (-6.6 to 0.1) | |
| Hearing loss and tinnitus | -15.5 (-24.8 to -6.3) | |
| Role Physical (RP) | | 0.002 |
| No auditory complications | Reference | |
| Hearing loss only | 0.1 (-2.5 to 2.7) | |
| Tinnitus only | -4.5 (-7.5 to -1.4) | |
| Hearing loss and tinnitus | -8.8 (-15.2 to -2.5) | |
| Role Emotional (RE) | | 0.053 |
| No auditory complications | Reference | |
| Hearing loss only | -2.0 (-6.2 to 2.2) | |
| Tinnitus only | -4.0 (-7.2 to -0.8) | |
| Hearing loss and tinnitus | -4.3 (-11.0 to 2.3) | |
| Bodily Pain (BP) | | < 0.001 |
| No auditory complications | Reference | |
| Hearing loss only | -1.1 (-3.5 to 1.2) | |
| Tinnitus only | -4.4 (-7.0 to -1.7) | |
| Hearing loss and tinnitus | -7.6 (-11.7 to -3.5) | |
| Mental Health (MH) | | 0.007 |
| No auditory complications | Reference | |
| Hearing loss only | -2.3 (-5.1 to 0.6) | |
| Tinnitus only | -4.5 (-7.8 to -1.1) | |
| Hearing loss and tinnitus | -4.3 (-8.3 to -0.3) | |
| Vitality (VT) | | < 0.001 |
| No auditory complications | Reference | |
| Hearing loss only | -3.0 (-6.1 to 0.1) | 7 |
| Tinnitus only | -8.7 (-12.2 to -5.2) | |
| Hearing loss and tinnitus | -8.6 (-13.1 to -4.2) | |

TABLE 3 Continued.

| Health Domains | Coef. (95%-CI) | P^{c} |
|---|---|---------|
| General Health (GH) | , , | < 0.001 |
| No auditory complications | Reference | |
| Hearing loss only | -2.6 (-6.1 to 0.9) | |
| Tinnitus only | -7.2 (-11.0 to -3.4) | |
| Hearing loss and tinnitus | -11.4 (-15.8 to -7.0) | |
| Social Functioning (SF) | | < 0.001 |
| No auditory complications | Reference | |
| Hearing loss only | -1.6 (-5.0 to 1.8) | |
| Tinnitus only | -7.0 (-10.4 to -3.6) | |
| Hearing loss and tinnitus | -10.0 (-16.2 to -3.9) | |
| Global Summary Scores | Coef. (95%-CI) | P^{c} |
| PCS | | < 0.001 |
| No auditory complications | Reference | |
| Hearing loss only | -0.6 (-3.5 to 2.2) | |
| | -0.0 (-3.3 to 2.2) | |
| Tinnitus only | -5.4 (-8.8 to -1.9) | |
| | , | |
| Tinnitus only | -5.4 (-8.8 to -1.9) | <0.001 |
| Tinnitus only Hearing loss and tinnitus | -5.4 (-8.8 to -1.9) | <0.001 |
| Tinnitus only Hearing loss and tinnitus MCS | -5.4 (-8.8 to -1.9) -14.5 (-21.9 to -7.1) | <0.001 |
| Tinnitus only Hearing loss and tinnitus MCS No auditory complications | -5.4 (-8.8 to -1.9) -14.5 (-21.9 to -7.1) Reference | <0.001 |
| Tinnitus only Hearing loss and tinnitus MCS No auditory complications Hearing loss only | -5.4 (-8.8 to -1.9) -14.5 (-21.9 to -7.1) Reference -2.9 (-6.2 to 0.5) | <0.001 |

Abbreviations: PCS, physical component summary; MCS, mental component summary.

^aAdjusted for: age at survey (continuous, in years); age at cancer diagnosis (continuous, in years); type of cancer diagnosis (according ICCC-3); history of relapse (yes/no); surgery (yes, no); chemotherapy (yes, no); radiotherapy (yes, no); type of cancer diagnosis (according ICCC-3); history of relapse (yes/no); surgery (yes, no); chemotherapy (yes, no); radiotherapy (yes, no); country of data provider.

^bWe included the cohorts from CH, CZ, and FR for the analysis (N=1,668) but excluded the cohort from Germany (n=4,650) because no data on tinnitus was available for the German cohort.

^c*P*-value calculated from Wald test.




FIGURE 1 Prevalence of self-reported hearing loss at the time of the study (N=6,318). *P*-values are calculated from chi²-statistics comparing prevalence between survivors of leukemia with survivors of other tumor types. Abbreviations: CNS, central nervous system.




FIGURE 2 Prevalence of self-reported tinnitus at the time of the study (N=1,668). Data from the cohorts of CH, CZ, and FR are shown. No data on tinnitus was available for the German cohort (n=4,650).

P-values are calculated from chi²-statistics comparing prevalence between survivors of leukemia with survivors of other tumor types. Abbreviations: CNS, central nervous system.




FIGURE 3 The two spider charts (A, B) show norm-based mean scores for all eight health domains and the two summary scores of the SF-36 comparing [A] CCS with hearing loss and normal hearing (N=6,318) and [B] CCS with tinnitus only, tinnitus and hearing loss, and without tinnitus (N=1,668). We included the cohorts from CH, CZ, and FR for the analysis of the association of tinnitus on HRQoL [B] (N=1,668) but excluded the cohort from Germany (n=4,650) because no data on tinnitus was available for the German cohort

Higher scores indicate better HRQoL. Normal population (shown as dashed line) has an estimated mean score of 50 with a standard deviation of 10 for all HRQoL scores of the SF-36. Raw data of the figure are shown in the supplement (Supplement Table S2, S3).

Abbreviations: PF, physical functioning; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotional; MH, mental health; PCS, physical component summary; MCS, mental component summary.